News


All series


All News

Patients with end-stage, age-related macular degeneration finally may have hope of regaining some of their central vision thanks to the recent FDA approval of a miniature telescope that can be implanted in the anterior segment.

Ketorolac tromethamine ophthalmic solution had a highly beneficial effect on visual acuity after cataract surgery in a recent study, according to one expert.

Here's the story of a successful optometrist who is equally talented at trapshooting.

Besifloxacin ophthalmic suspension 0.6% provides potent broad-spectrum antibacterial coverage coupled with favorable safety, tolerability and dosing convenience.

It's been 40 years since Alvin Toffler predicted the accelerating pace of change in his book Future Shock in 1970.

Keeping up with current pharmacologic advances and new formulations is one of the keys to better patient outcomes.

In a quantitative determination of the prophylactic effectiveness of two commercially available ocular fluoroquinolones within the anterior chamber of rabbit eyes, moxifloxacin ophthalmic solution 0.5% demonstrated significantly greater bacterial killing than besifloxacin ophthalmic suspension 0.6%.

Effective management of the patient with low vision requires considerably more of an optometrist than the ability to perform a low vision exam.

In an effort to convince optometrists to become board certified, the American Board of Optometry has engaged in deceptive and false advertising and unfair competition, according to a lawsuit filed by the AOS against the ABO.

A final analysis of a 2-year study with cyclosporine ophthalmic emulsion 0.05% used for the treatment of dry eye syndrome shows that patient have continued improvement in their dry eye parameters over a 2-year period, according to one expert.

Johnson & Johnson Vision Care Inc. may continue selling its Acuvue Oasys contact lenses, even though its manufacturing infringes CIBA Vision Corp.'s patent, in order to protect "millions of innocent contact lens wearers" who would have to be refitted with a different brand, a federal judge has ruled.

The availability of a new formulation of gatifloxacin ophthalmic solution containing 0.5% of active ingredient provides optometrists with a valuable option for addressing the growing problem of resistance among some important ocular pathogens.